|
RIF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.59120005639136E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.63219998522624E-09 |
| Normal-vs-Stage2 |
5.11969999728024E-09 |
| Normal-vs-Stage3 |
3.78650000243397E-10 |
| Normal-vs-Stage4 |
1.64929958579307E-10 |
| Stage1-vs-Stage2 |
4.715000E-01 |
| Stage1-vs-Stage3 |
1.810010E-01 |
| Stage1-vs-Stage4 |
6.420400E-02 |
| Stage2-vs-Stage3 |
8.062600E-01 |
| Stage2-vs-Stage4 |
4.948800E-01 |
| Stage3-vs-Stage4 |
5.934600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.21300003375069E-09 |
| Normal-vs-AfricanAmerican |
1.89556999999896E-05 |
| Normal-vs-Asian |
7.92479970534998E-10 |
| Caucasian-vs-AfricanAmerican |
2.767200E-01 |
| Caucasian-vs-Asian |
4.362800E-01 |
| AfricanAmerican-vs-Asian |
1.270020E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.46890343911377E-11 |
| Normal-vs-Female |
2.67760003058726E-09 |
| Male-vs-Female |
2.594100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.30110000551298E-08 |
| Normal-vs-Age(41-60Yrs) |
4.0089997987991E-10 |
| Normal-vs-Age(61-80Yrs) |
4.33070024286053E-10 |
| Normal-vs-Age(81-100Yrs) |
4.660100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.441700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.075990E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.812000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.469400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.984000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.419200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.817200E-01 |
| Classical-VS-Follicular |
6.443800E-02 |
| Classical-VS-Other |
1.034390E-01 |
| Classical-VS-Normal |
1.04520000432373E-08 |
| Tall-VS-Follicular |
9.254000E-01 |
| Tall-VS-Other |
2.927600E-01 |
| Tall-VS-Normal |
2.37760000576515E-09 |
| Follicular-VS-Other |
3.833200E-01 |
| Follicular-VS-Normal |
8.39679992203912E-10 |
| Other-VS-Normal |
9.08379999997599E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.75670050623E-10 |
| Normal-vs-N1 |
5.94799987041483E-10 |
| N0-vs-N1 |
6.040400E-01 |
|
|
